Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 12, 2010, Pages 2434-2442

  Rauch, Bernhard H ^a   Rosenkranz, Anke C ^a   Ermler, Swen ^a   Böhm, Andreas ^a   Driessen, Julia ^a   Fischer, Jens W ^b   Sugidachi, Atsuhiro ^c   Jakubowski, Joseph A ^d   Schrör, Karsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c DAIICHI SANKYO CO   (Japan)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

atherosclerosis; inflammation; P2Y12 receptor; thrombin; vascular smooth muscle

Indexed keywords

2 METHYLTHIOADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; R 138727; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; CAROTID ARTERY DISEASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RNA ANALYSIS; RNA INTERFERENCE; THROMBOCYTE ACTIVATION; TISSUE DISTRIBUTION; VASCULAR SMOOTH MUSCLE;

ADENOSINE DIPHOSPHATE; CAROTID ARTERY DISEASES; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP; HUMANS; INTERLEUKIN-6; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PIPERAZINES; PURINERGIC P2Y RECEPTOR AGONISTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RNA INTERFERENCE; RNA, MESSENGER; THIONUCLEOTIDES; THROMBIN; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 78650420253     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.213702     Document Type: Article

References (37)

1. Garg R, Uretsky BF, Lev EI. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2007;70:388-406.
2. Siller-Matula J, Schrör K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost. 2007; 97:385-393.
3. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med. 2007;12:113-122.
4. Evans DJ, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE, Storey RF. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation. 2009;119:116-122.
5. Pitchford SC. Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol. 2007;152:987-1002.
6. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207. (Pubitemid 32144286)
7. Burnstock G. Vessel tone and remodeling. Nat Med. 2006;12:16-17.
8. Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J. 1986;233:309-319.
9. Idzko M, Hammad H, Van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow JC Jr, Lambrecht BN. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. 2007;13: 913-919.
10. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci. 2006;27:211-217.
11. Shanker G, Kontos JL, Eckman DM, Wesley-Farrington D, Sane DC. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis. 2006;22:213-220.
12. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudb-jartsson T, Erlinge D. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:1810-1815.
13. Furie B, Furie BC. In vivo thrombus formation. J Thromb Haemost. 2007;5(suppl 1):12-17.
14. Rauch BH, Millette E, Kenagy RD, Daum G, Clowes AW. Thrombin-and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res. 2004;94:340-345.
15. Pape R, Rauch BH, Rosenkranz AC, Kaber G, Schror K. Transcriptional inhibition of protease-activated receptor-1 expression by prostacyclin in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:534-540.
16. Osinski MT, Rauch BH, Schror K. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol. 2001;59:1044-1050.
17. Bodor ET, Waldo GL, Hooks SB, Corbitt J, Boyer JL, Harden TK. Purification and functional reconstitution of the human P2Y12 receptor. Mol Pharmacol. 2003;64:1210-1216.
18. Niemetz J, Fallon JT, Harrington E, Hathcock J. Rapid generation of thrombin by atheroma and platelets. J Thromb Haemost. 2004;2:321-326.
19. Chiu YC, Fong YC, Lai CH, Hung CH, Hsu HC, Lee TS, Yang RS, Fu WM, Tang CH. Thrombin-induced IL-6 production in human synovial fibroblasts is mediated by PAR1, phospholipase C, protein kinase COL, c-Src, NF-KB and p300 pathway. Mol Immunol. 2008;45:1587-1599.
20. Bretschneider E, Wittpoth M, Weber AA, Glusa E, Schror K. Activation of NFKB is essential but not sufficient to stimulate mitogenesis of vascular smooth muscle cells. Biochem Biophys Res Commun. 1997;235: 365-368.
21. Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost. 2007;5:577-582.
22. Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, Asai F. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005;94:593-598.
23. Srinivasan S, Mir F, Huang JS, Khasawneh FT, Lam SC, Le Breton GC. The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate trieth-ylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem. 2009;284:16108-16117.
24. Bretschneider E, Kaufmann R, Braun M, Nowak G, Glusa E, Schror K. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol. 2001;132: 1441-1446.
25. Bretschneider E, Spanbroek R, Lotzer K, Johann Richard Habenicht A, Schror K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost. 2003;90:704-709.
26. Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol. 2008;153(suppl 1):S263-S282.
27. Martorell L, Martinez-Gonzalez J, Rodriguez C, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activated receptors (PARs) in athero-thrombosis. Thromb Haemost. 2008;99:305-315.
28. Ardissino D, Merlini PA, Bauer KA, Bramucci E, Ferrario M, Coppola R, Fetiveau R, Lucreziotti S, Rosenberg RD, Mannucci PM. Thrombogenic potential of human coronary atherosclerotic plaques. Blood. 2001;98: 2726-2729.
29. Rauch BH, Bretschneider E, Braun M, Schror K. Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res. 2002;90:1122-1127.
30. Packham MA, Mustard JF. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. Semin Thromb Hemost. 2005;31:129-138.
31. Schoneberg T, Hermsdorf T, Engemaier E, Engel K, Liebscher I, Thor D, Zierau K, Rompler H, Schulz A. Structural and functional evolution of the P2Y(12)-like receptor group. Purinergic Signal. 2007;3:255-268.
32. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation. 1994;90:1908-1918.
33. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation. 2003;108:2971-2973.
34. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kre-mastinos DT. Inflammatory and non-invasive vascular markers: the mul-timarker approach for risk stratification in coronary artery disease. Atherosclerosis. 2008;199:3-11.
35. Inoue K, Hosoi J, Denda M. Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes. J Invest Dermatol. 2007;127:362-371.
36. Wang Z, Castresana MR, Newman WH. NF-KB is required for TNF-a-directed smooth muscle cell migration. FEBS Lett. 2001;508:360-364.
37. Clahsen T, Schaper F. Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration. J Leukocyte Biol. 2008;84:1521-1529.